Promising Anticancer Activity of [Bis(1,8-quinolato)palladium (II)] Alone and in Combination

Due to similar coordination chemistry of palladium and platinum, a large number compounds as well have been investigated for their anticancer activity. In the present study, we describe synthesis, characterization, activity complex [Bis(1,8-quinolato)palladium (II)], coded NH3 against seven different cancer cell lines. is found higher antitumor than cisplatin both parent ovarian A2780 line cisplatin-resistant Also, has lower IC50 value in HT-29 colorectal line. The due presence bulky 8-Hydroxyquinoline ligand, thus reducing its reactivity. Proteomic study identified significantly expressed proteins which validated through bioinformatics. be less toxic at 2.5 mg/kg 5 dosages on mice models. Binary combinations with curcumin epigallocatechin gallate (EGCG) demonstrated dose sequence-dependent synergism All preclinical studies indicate promising therapeutic potential (II)] an drug.